VTRS · Earnings call · 2026Q2T · Full report

Nashik Manufacturing Disruptions

Viatris Inc · 2026-08-06 · Importance 40 · Surprise 42 · In source text

The Nashik manufacturing facility experienced a first-quarter fire and May 2026 FDA inspection observations, prompting a comprehensive remediation plan and intermittent manufacturing disruptions. Management expects the disruption to affect mainly lower-margin oral solid-dose generics in emerging markets and certain generic products in Europe, with the largest impact in the third quarter and moderation in the fourth quarter. The disruption is expected to reduce second-half revenue by approximately $100 million to $150 million, although management characterized the affected products as numerous smaller items, with no single product exceeding $20 million in revenue. Viatris expects the issue to be short term and to be largely resolved by year-end or early 2027.

Key facts

• Anticipated impact of supply disruptions (primarily Nashik) to total revenues in H2 2026: between $100 million and $150 million
• Initiated a comprehensive remediation plan and are communicating with the FDA and external experts regarding Nashik May 2026 inspection observations
• Supply disruptions primarily from Nashik are expected to primarily impact low-margin oral solid dose generics in emerging markets and certain generic products in Europe
• Viatris sees the Nashik supply disruption impact larger in Q3 2026 and moderating in Q4 2026, expecting disruption to be shorter term
• Nashik disruption affects a lot of smaller products; no one product there is more than $20 million in revenue

Impact estimates